Ethical considerations of industry-sponsored research: The use of human subjects

Journal of the American College of Nutrition

Volumn 15, Issue , 1996, Pages 35S-40S

  Moreno, Jonathan D ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Ethics; Human subjects; Industry; Research

Indexed keywords

CLINICAL RESEARCH; CONFERENCE PAPER; ETHICS; FINANCE; INDUSTRY; INVESTMENT; MARKETING;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

CLINICAL TRIALS; ETHICS, MEDICAL; HUMAN EXPERIMENTATION; HUMANS;

EID: 0029849538     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.1996.10720474     Document Type: Article

References (32)

1. PercivalT: "Medical Ethics; or a Code of Institutes and Precepts, Adapted to the Professional Conduct of Physicians and Surgeons." Manchester: S. Russell, 1803.
2. MyerIS: "Life and Letters of Dr. William Beaumont," 3rd ed, St. Louis: Mosby, 1981.
3. BernardC: "Introduction to Experimental Medicine." New York: Dover, 1957.
4. SassH-M: Reichsrundschreiben 1931: Pre-Nuremberg German Regulations Concerning New Therapy and Human Experimentation. J Med and Phil8:99-111, 1983.
5. United States v. Karl Brandt, Trials of War Criminals Before the Nuremberg Military Tribunls under Control Council Law No. 10, Vo1s. 1 and 2. ''The Medical Case" (Military Tribunal I, 1947; Washington, D.C.: U.S. Government Printing Office, 1948-49).
6. LedererSE, GrodinMA: Historical overview: Pediatric experimentation. In Grodin MA, Glantz LH (eds): "Children as Research Subjects." New York: Oxford University Press, pp 3-25, 1994.
7. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: "The Belmont Report: Ethical Guidelines for the Protection of Human Subjects of Research." DHEW Publication No. (08)78-0012, 1978.
8. Federal Policies for the Protection of Human Subjects: Notes and Rules. 56 Fed. Reg., 28002-28032, June18, 1991.
9. VarmusH: Shattuck lecture-Biomedical research enters the steady state. N Engl J Med333:811-815, 1995.
10. BlankIH: Industry-funded dermatologicresearch within academic in the United States: Fiscal and ethical considerations. J Investigative Derm98:265-268, 1992.
11. TopolEJ, ArmstrongP, Van de WerfFet al.: Confronting the issues of patient safety and investigator conflict of interest in an international trial of myocardial reperfusion, J Am Coli Cardiol 19:1123-12.
12. Rodwin MA: "Medicine, Money & Morals: Physicians' Conflict of Interest." New York: Oxford University Press, 1993.
13. Ray WA, Griffin MR, Avoid I: Evaluating drugs after their approval for clinical use. N Engl J Med 329:2029-2032, 1993.
14. Shimm DS, Spece RG: Industry Reimbursement for entering patients into clinical trials: Legal and ethical issues. Annals Int Med 115:148-151, 1991.
15. ShimmDS, SpeceRG: Ethical issues and clinical trials. Drugs46:579-584, 1993.
16. DavidsonRA: Source of funding and outcome of clinical trials. J Gen Int Med1:155-158, 1986.
17. MooreV. The Regents of the University of California, 271 Cal. Reptr. 146 (Cal. 1990).
18. FinkelMJ: Should informed consent include information on how research is funded?IRB13:1-2, 1991.
19. LevineR: Advice on compensation: More responses to DHEW's "Interim Final Regulation." IRB1:5, 1979.
20. VandenBurgM, DewsI: Defining surveillance. BMJ:310:1662, 1995.
21. KesslerDA, RoseJL, TempleRJet al.: Therapeutic-class warsDrug promotion in a competitive marketplace. N Engl J Med 331:1352-1353, 1994.
22. Anderson IR, lameton A, Reitmeier PI, Prentice E: The case of two devices: Disclosure to subjects following Phase IV ("postmarketing") research. IRB17:6-9, 1995.
23. MartinFH: "Fifty Years of Medicine and Surgery." Chicago: The Surgical Publishing Company of Chicago, 1934.
24. LaPuma I, Stocking CB, Rhoades WD, Darling CM: Financial ties as part of informed consent to postmarketing research. BMJ310: 1660-1661, 1995.
25. RodwinMA: Physicians' conflict of interest: The limitations of disclosure. N Engl J Med321:1405-1408, 1989.
26. LaPuma I: Should patients know how much doctors are paid for prescribing Phase IV pharmaceuticals" J Outcomes Management2:14-17, 1995.
27. Council on Ethical and ludicial Affairs of the American Medical Association: "Conflicts of Interest: Biomedical Research. 1992Code of Medical Ethics Current Opinions." Chicago: American Medical Association, 1992.
28. Biomedical Ethics Committee, RCPSC: Ethical responsibilities of physicians in their dealings with pharmaceutical companies. Annals RCPSC23:45-48, 1990.
29. Medicines Control Agency, Committee on Safety of Medicines, Royal College of Physicians, British Medical Association, and Association of the British Pharmaceutical Industry: Guidelines for company-sponsored safety assessment of marketed medicines. Br J Pharmacol38:93-97, 1994.
30. MooreTJ: "Deadly Medicine." New York: Simon & Schuster, 1995.
31. President's Advisory Committee on Human Radiation Experiments: "Final Report." Washington, DC: U.S. Government Printing Office, 1995.
32. Thompson DF: Understanding financial conflicts of interest. N Engl J Med 329:573-576, 1993. VOL 28, 1992.